Nogo receptor binding protein
View Patent ↗The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
1. An isolated polynucleotide encoding a soluble fragment of SEQ ID NO:2, wherein expression of said polynucleotide in a cell produces said soluble fragment of SEQ ID NO: 2 that is capable of decreasing inhibition of axonal growth of a central nervous system neuron.
2. The isolated polynucleotide of claim 1 , wherein the a soluble fragment of SEQ ID NO:2 is selected from the group consisting of:
(a) a polypeptide comprising amino acids 34-532 of SEQ ID NO:2;
(b) a polypeptide comprising amino acids 417-531 of SEQ ID NO:2;
(c) a polypeptide comprising amino acids 425-531 of SEQ ID NO:2;
(d) a polypeptide comprising amino acids 1-531 of SEQ ID NO:2;
(e) a polypeptide comprising amino acids 433-493 of SEQ ID NO:2;
(f) a polypeptide comprising an Sp35LRR domain, an Sp35 basic region C-terminal to the LRR domain, and an Sp35 immunoglobulin (Ig) domain C-terminal to the basic region, but lacks a transmembrane domain;
(g) a polypeptide comprising an Sp35 Ig domain, but lacking an Sp35 LRR domain, an Sp35 basic region, a transmembrane domain, and a cytoplasmic domain;
(h) a polypeptide comprising an Sp35 LRR domain, but lacking an Sp35 Ig domain, an Sp35 basic region, a transmembrane domain, and a cytoplasmic domain, and
(i) a polypeptide as in (f), further lacking a cytoplasmic domain;
wherein said soluble fragment is capable of decreasing inhibition of axonal growth of a central nervous system neuron.
3. The polynucleotide of claim 1 , wherein said polynucleotide further encodes a heterologous polypeptide fused to said soluble fragment of SEQ ID NO:2.
4. The polynucleotide of claim 3 , wherein said heterologous polypeptide is selected from the group consisting of an Ig polypeptide, a serum albumin polypeptide, a targeting polypeptide, a reporter polypeptide, a human NgR1 -binding polypeptide, one or more cysteine residues, and a purification-facilitating polypeptide.
5. The polynucleotide of claim 4 , wherein said heterologous polypeptide is selected from the group consisting of immunoglobulin Fc, human serum albumin or fragment thereof; a histidine tag, an oligodendrocyte-myelin glycoprotein or fragment thereof, a myelin associated glycoprotein or fragment thereof, and a Nogo66 glycoprotein or fragment thereof.
6. The isolated polynucleotide of claim 1 , wherein the soluble fragment of SEQ ID NO:2 is selected from the group consisting of:
(a) a polypeptide consisting of amino acids 454-458 of SEQ ID NO:2; and
(b) a polypeptide consisting of amino acids 453-458 of SEQ ID NO:2.
7. The polynucleotide of claim 6 , wherein said polynucleotide further encodes a heterologous polypeptide fused to said soluble fragment of SEQ ID NO:2.
8. A composition comprising a pharmaceutically acceptable carrier and the polynucleotide of claim 1 .
9. A vector comprising the polynucleotide of claim 1 .
10. The vector of claim 9 , wherein said polynucleotide is operatively linked to an expression control sequence.
11. The vector of claim 10 , wherein said vector is a viral vector.
12. The vector of claim 11 , wherein said viral vector is selected from the group consisting of an adenoviral vector, a lentiviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, and a herpes simplex viral vector.
13. A host cell comprising the vector of claim 10 .
14. The host cell of claim 13 , which expresses said soluble polypeptide.
15. A method for producing an Sp35 polypeptide comprising culturing the host cell of claim 14 and recovering said Sp35 polypeptide from the culture medium.
16. An isolated polypeptide encoded by the polynucleotide of claim 1 .
17. The polypeptide of claim 16 , wherein said polypeptide is produced synthetically.
18. The polypeptide of claim 16 , wherein said polypeptide is conjugated to a polymer.
19. The polypeptide of claim 18 , wherein said polymer is selected from the group consisting of a polyalkylene glycol, a sugar polymer, and a polypeptide.
20. The polypeptide of claim 19 , wherein said polyalkylene glycol is polyethylene glycol (PEG).
21. The polypeptide of claim 18 , wherein said polypeptide is conjugated to 1, 2, 3 or 4 polymers.
22. The polypeptide of claim 21 , wherein the total molecular weight of the polymers is from 20,000 Da to 40,000 Da.
23. An isolated polypeptide encoded by the polynucleotide of claim 3 .
24. An isolated polypeptide encoded by the polynucleotide of claim 6 .
25. The polypeptide of claim 24 , wherein said polypeptide is cyclized.
26. An isolated polypeptide encoded by the polynucleotide of claim 7 .
27. A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 16 .
28. The composition of claim 27 , further comprising a supplementary active compound selected from the group consisting of an anti-NgR1 antibody or binding fragment thereof and a soluble NgR1 polypeptide.
29. A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 24 .